163 related articles for article (PubMed ID: 34865071)
21. Vaginal microbiota of asymptomatic bacterial vaginosis and vulvovaginal candidiasis: Are they different from normal microbiota?
Pramanick R; Mayadeo N; Warke H; Begum S; Aich P; Aranha C
Microb Pathog; 2019 Sep; 134():103599. PubMed ID: 31212037
[TBL] [Abstract][Full Text] [Related]
22. The Vaginal Microbiota Among Adolescent Girls in Tanzania Around the Time of Sexual Debut.
Francis SC; Crucitti T; Smekens T; Hansen CH; Andreasen A; Jespers V; Hardy L; Irani J; Changalucha J; Baisley K; Hayes R; Watson-Jones D; Buvé A
Front Cell Infect Microbiol; 2020; 10():305. PubMed ID: 32670894
[TBL] [Abstract][Full Text] [Related]
23. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.
Balkus JE; Palanee-Phillips T; Reddy K; Siva S; Harkoo I; Nakabiito C; Kintu K; Nair G; Chappell C; Kiweewa FM; Kabwigu S; Naidoo L; Jeenarain N; Marzinke M; Soto-Torres L; Brown ER; Baeten JM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e47-e51. PubMed ID: 28542081
[TBL] [Abstract][Full Text] [Related]
24. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.
Baeten JM; Palanee-Phillips T; Brown ER; Schwartz K; Soto-Torres LE; Govender V; Mgodi NM; Matovu Kiweewa F; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Pather A; Naidoo L; Husnik M; Richardson BA; Parikh UM; Mellors JW; Marzinke MA; Hendrix CW; van der Straten A; Ramjee G; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Mayo A; Scheckter R; Berthiaume J; Livant E; Jacobson C; Ndase P; White R; Patterson K; Germuga D; Galaska B; Bunge K; Singh D; Szydlo DW; Montgomery ET; Mensch BS; Torjesen K; Grossman CI; Chakhtoura N; Nel A; Rosenberg Z; McGowan I; Hillier S;
N Engl J Med; 2016 Dec; 375(22):2121-2132. PubMed ID: 26900902
[TBL] [Abstract][Full Text] [Related]
25. Two into one does go: Formulation development of a multipurpose combination vaginal ring releasing dapivirine and metronidazole for prevention of HIV infection and treatment of bacterial vaginosis.
Zhao X; Boyd P; Bashi YD; Murphy DJ; McCoy CF; Coulter S; Laverty G; Malcolm RK
Int J Pharm; 2023 Dec; 648():123572. PubMed ID: 37926178
[TBL] [Abstract][Full Text] [Related]
26. The Vaginal Microbiota and Behavioral Factors Associated With Genital Candida albicans Detection in Reproductive-Age Women.
Brown SE; Schwartz JA; Robinson CK; OʼHanlon DE; Bradford LL; He X; Mark KS; Bruno VM; Ravel J; Brotman RM
Sex Transm Dis; 2019 Nov; 46(11):753-758. PubMed ID: 31517769
[TBL] [Abstract][Full Text] [Related]
27. Association Between Vaginal Bacterial Microbiota and Vaginal Yeast Colonization.
Eastment MC; Balkus JE; Richardson BA; Srinivasan S; Kimani J; Anzala O; Schwebke J; Fiedler TL; Fredricks DN; McClelland RS
J Infect Dis; 2021 Mar; 223(5):914-923. PubMed ID: 32726445
[TBL] [Abstract][Full Text] [Related]
28. Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring.
McCoy CF; Murphy DJ; Boyd P; Derrick T; Spence P; Devlin B; Malcolm RK
J Pharm Sci; 2017 Aug; 106(8):2015-2025. PubMed ID: 28456732
[TBL] [Abstract][Full Text] [Related]
29. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
[TBL] [Abstract][Full Text] [Related]
30. Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.
Taneva E; Sinclair S; Mesquita PM; Weinrick B; Cameron SA; Cheshenko N; Reagle K; Frank B; Srinivasan S; Fredricks D; Keller MJ; Herold BC
JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997295
[TBL] [Abstract][Full Text] [Related]
31. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
32. Drug stability and product performance characteristics of a dapivirine-releasing vaginal ring under simulated real-world conditions.
Murphy DJ; McCoy CF; Boyd P; Derrick T; Spence P; Devlin B; Malcolm RK
Int J Pharm; 2019 Jun; 565():351-357. PubMed ID: 31085254
[TBL] [Abstract][Full Text] [Related]
33. Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.
Thurman AR; Schwartz JL; Ravel J; Gajer P; Marzinke MA; Yousefieh N; Anderson SM; Doncel GF
PLoS One; 2019; 14(5):e0217229. PubMed ID: 31107913
[TBL] [Abstract][Full Text] [Related]
34. Vaginal microflora in postmenopausal women who have not received estrogen replacement therapy.
Hillier SL; Lau RJ
Clin Infect Dis; 1997 Sep; 25 Suppl 2():S123-6. PubMed ID: 9310650
[TBL] [Abstract][Full Text] [Related]
35. Association of vaginal dysbiosis and biofilm with contraceptive vaginal ring biomass in African women.
Hardy L; Jespers V; De Baetselier I; Buyze J; Mwambarangwe L; Musengamana V; van de Wijgert J; Crucitti T
PLoS One; 2017; 12(6):e0178324. PubMed ID: 28594946
[TBL] [Abstract][Full Text] [Related]
36. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589
[TBL] [Abstract][Full Text] [Related]
37. Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance.
Murphy DJ; Lim D; Armstrong R; McCoy CF; Bashi YHD; Boyd P; Derrick T; Spence P; Devlin B; Malcolm RK
Drug Deliv Transl Res; 2023 Aug; 13(8):2072-2082. PubMed ID: 34674162
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.
Noguchi LM; Hoesley C; Kelly C; Scheckter R; Bunge K; Nel A; Marzinke MA; Hendrix CW; Dezzutti CS; Hillier SL; Bogen DL; Piper JM; Beigi RH
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602513
[TBL] [Abstract][Full Text] [Related]
39. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
40. Development of dapivirine vaginal ring for HIV prevention.
Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
